- Home
- SGN vs AWH Comparison
SGN vs AWH Comparison
Compare SGN & AWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- AWH
- Stock Information
- Founded
- SGN 2019
- AWH 1993
- Country
- SGN United States
- AWH United States
- Employees
- SGN N/A
- AWH N/A
- Industry
- SGN
- AWH Medical/Dental Instruments
- Sector
- SGN
- AWH Health Care
- Exchange
- SGN Nasdaq
- AWH Nasdaq
- Market Cap
- SGN 1.6M
- AWH 1.6M
- IPO Year
- SGN 2023
- AWH N/A
- Fundamental
- Price
- SGN $0.72
- AWH $0.10
- Analyst Decision
- SGN
- AWH Buy
- Analyst Count
- SGN 0
- AWH 2
- Target Price
- SGN N/A
- AWH $4.40
- AVG Volume (30 Days)
- SGN 143.3K
- AWH 12.9M
- Earning Date
- SGN 05-14-2025
- AWH 03-27-2025
- Dividend Yield
- SGN N/A
- AWH N/A
- EPS Growth
- SGN N/A
- AWH N/A
- EPS
- SGN N/A
- AWH N/A
- Revenue
- SGN $576,488.00
- AWH $9,182,000.00
- Revenue This Year
- SGN N/A
- AWH $11.87
- Revenue Next Year
- SGN N/A
- AWH $79.10
- P/E Ratio
- SGN N/A
- AWH N/A
- Revenue Growth
- SGN 147.76
- AWH 0.31
- 52 Week Low
- SGN $0.65
- AWH $0.08
- 52 Week High
- SGN $36.72
- AWH $3.63
- Technical
- Relative Strength Index (RSI)
- SGN 30.31
- AWH 28.07
- Support Level
- SGN $0.66
- AWH $0.09
- Resistance Level
- SGN $0.81
- AWH $0.36
- Average True Range (ATR)
- SGN 0.09
- AWH 0.01
- MACD
- SGN 0.06
- AWH 0.01
- Stochastic Oscillator
- SGN 12.90
- AWH 15.00
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.